Ein Shlishit 2025: Orders Are Real, but the Serial-Production Transition Still Runs Through Credit, Inventory, and Dilution

Company Introduction

Ein Shlishit is no longer just an early-stage development story looking for its first commercial proof. In 2025 it already sold NIS 20.9 million, ended the year with NIS 44.2 million of backlog, expanded its production setup, and moved into a new site designed for both offices and manufacturing. Anyone looking only at revenue growth, backlog, and the broader defense backdrop could conclude that the company has already moved past proof-of-market and into harvest mode. That is too superficial a read.

What is working now is the demand side. The Israeli Ministry of Defense remains the anchor customer, MEDUZA is still the core revenue engine, ARGOS already climbed to 30% of sales, and the company continued to collect orders from overseas customers as well. In addition, as of April 3, 2026, market capitalization stood at roughly NIS 224.6 million. That means the market is already pricing the next phase more than it is pricing what the company actually earned in 2025.

What is still not clean is the bottleneck. The main issue today is not whether the technology is finding demand, but whether that demand can be turned into gross profit, cash, and growth that does not need to be bought again through short-term credit, inventory build, and external capital. Revenue rose 19%, but gross profit fell 58% to only NIS 2.38 million, operating loss widened to NIS 11.7 million, and cash flow from operations remained negative at NIS 10.3 million.

That matters now because 2026 looks like a proof year, not a breakout year. The company has more orders, more production capacity, more products, and a potentially strategic funding path through EDGE. But for the read to improve over the next few quarters, three things need to happen together: serial deliveries have to come with better margins, working-capital pressure has to ease, and customer diversification has to start looking commercial rather than only aspirational.

The 2025 Economic Map

This table sets the right angle. Ein Shlishit has already proven that it has products, an anchor customer, and a real order path. It has not yet proven that this growth can become clean profitability. The key question is whether 2025 was a one-off investment year ahead of serial production, or simply another stage in a growth story that buys revenue through lower margins and weaker balance-sheet flexibility.

The chart shows the main paradox. The top line keeps rising, but everything beneath it is deteriorating. That is the center of the story. A company with real demand eventually needs to show better margin structure, not only higher sales volume.

Events And Triggers

EDGE still looks like funding and market access first, revenue later

On January 28, 2025, the company signed the EDGE investment agreement for roughly $10 million in exchange for about 30% to 32% of fully diluted equity. This matters on two levels. On one side, it can materially improve the funding picture and potentially open new markets through a joint venture. On the other side, it does so at a meaningful dilution cost, while the JV itself is still optional and its commercial terms are not yet fully formed.

The post-balance-sheet picture improved, but it did not fully close. On February 15, 2026, shareholders approved the deal, and on March 19, 2026 approval was received for the share listing. By the report date, about $2 million had already been transferred as an advance, and management said the balance should arrive in the near term. Practically, that means the market got confirmation that the deal is alive, but not yet proof that it has already solved the funding question or the sales question.

The serial-production transition has already moved from the lab into the balance sheet

On February 26, 2025, the subsidiary signed a lease agreement for about 850 square meters in Netanya, and in July 2025 it moved into the new office and production facility. This is not a minor operating detail. It appears almost everywhere in the numbers: the right-of-use asset rose to NIS 4.08 million, lease liabilities climbed to NIS 4.13 million, property and equipment increased to NIS 1.64 million, and investing cash outflow moved from only NIS 27 thousand negative in 2024 to NIS 2.41 million negative in 2025.

That is the right strategic move if a real manufacturing scale-up is arriving. It becomes a burden if revenue recognition and cash collection continue to lag the pace of inventory build and fixed-cost expansion.

Orders kept coming, but management itself reminds the market that orders are not yet revenue

During 2025 the company recorded a meaningful order flow: roughly NIS 1 million from the Ministry of Defense in early January, a $620 thousand order in March, a NIS 4.8 million order in April, another NIS 8 million order in June, an $800 thousand order from two NATO-country customers in September, and another November sale to an existing NATO-based customer.

After the balance-sheet date, on March 11, 2026, the company also received a follow-on order of roughly NIS 4 million from a defense customer for serial systems, with expected execution over about half a year and potential for additional orders during the year. But the critical nuance is that the company explicitly stated that this amount is not yet defined as revenue until the point at which the order can no longer be cancelled. Even in the clearest positive near-term trigger, management itself asks the market not to confuse order flow with recognized revenue.

SensAI is interesting optionality, not the 2026 engine

On January 9, 2025, the company also entered a new platform with Mor Research Applications to commercialize pain-detection technology, and in May 2025 the subsidiary SensAI Vision was incorporated with Ein Shlishit holding 85%. This is an interesting technological option, but at this stage it does not explain 2025 and it does not finance 2026. Any attempt to reframe the company as a broad AI platform is still ahead of the actual financial evidence.

Efficiency, Profitability And Competition

The central failure of 2025 is not on the demand side, but on the quality-of-growth side. Revenue rose to NIS 20.9 million, yet cost of sales climbed to NIS 18.6 million, gross profit fell to NIS 2.38 million, and gross margin collapsed to 11.4% from 32.2% in 2024. That is too sharp a deterioration to dismiss as ordinary volatility.

Management provides the explanation, and it matters. The company explicitly says that margin erosion reflected higher development expense tied to the tender it won, the setup of a production line, and preparations for serial manufacturing. It also says it is strategically willing to take orders at lower margins in order to deepen market penetration and develop new products using its existing know-how. That was the defining management choice of 2025. The implication is that growth was not only pressured by cost timing. Part of it was deliberately bought through weaker near-term economics.

The mix sharpens the picture. MEDUZA remained the core product at 56% of revenue, but ARGOS jumped from 10% to 30% of sales. That is not just a commercial change. It is also an economic change. ARGOS and the ground-platform offering reflect deeper entry into project work, integration, and customer-specific adaptation. In other words, the company is moving into a place where order volume can rise fast, but where pre-revenue cost can also rise fast.

Another point a first read can miss is where the cost actually sits. Cost of sales already includes NIS 12.0 million of raw materials and NIS 9.4 million of payroll, while NIS 5.57 million was parked as an increase in work-in-progress inventory. That means a meaningful part of the 2025 manufacturing effort had not yet passed through the revenue line. So it is possible that 2025 gross margin reflects a temporary trough before serial scale. It is equally possible that it is already exposing the true cost structure of early serial deliveries.

Concentration makes the question harder. The Ministry of Defense alone generated NIS 17.655 million, or about 84% of total revenue. This is not only customer concentration. It is concentration in a single procurement ecosystem, a single approval chain, and a single pace of order flow. In the credit-risk note, the company says it has no significant exposure to one specific customer. From a pure bad-debt perspective that is understandable because the customer is a government body. From a business perspective, this is still a very heavy concentration risk.

The competitive edge also needs to be read correctly. The company faces larger players such as Rafael, Controp, NextVision, L3Harris Wescam, FLIR, and HGH, while arguing that it has an edge in passive optical detection, AI at the edge, and fast customer adaptation. That may be true. But it is still an edge that is being financed, not harvested. R&D expense rose to NIS 6.36 million in 2025, and the company’s product-investment table shows NIS 6.65 million invested in MEDUZA, NIS 5.4 million in ARGOS, and NIS 2.34 million in CHIMERA. The moat is still being built through spending rather than collected as stable profit.

Cash Flow, Debt And Capital Structure

The cash read here is an all-in cash-flexibility read. The right question is not how the business looks before real cash uses, but how much cash is left after operating outflows, investment, interest, lease cash, and financing friction. On that basis, 2025 was a very expensive transition year.

Year-end cash was only NIS 1.13 million, down from NIS 7.93 million a year earlier. Cash flow from operating activity was negative NIS 10.27 million, investing cash flow was negative NIS 2.41 million, and only NIS 5.87 million of positive financing cash flow prevented an even sharper decline. At the same time, the company paid NIS 1.42 million of cash interest and NIS 550 thousand of lease cash during the year.

The waterfall highlights what the revenue numbers hide. Ein Shlishit did not burn cash because it lacked orders. It burned cash because the shift into serial production required funding inventory, contract assets, production setup, interest, and lease commitments before the money came back in.

This chart matters more than any generic statement about growth. Contract assets rose to NIS 9.09 million, inventory jumped to NIS 11.49 million, suppliers and accruals increased to NIS 14.56 million, and short-term bank debt reached NIS 11.52 million, while cash itself fell sharply. In plain language, much of the year was financed by the bank and by suppliers while the cash balance deteriorated.

The company did end 2025 with positive working capital of NIS 1.4 million and positive equity of NIS 3.34 million, but those cushions are narrow relative to the new operating scale. That becomes even clearer because the company also states that, by the report date on March 31, 2026, cash stood at about NIS 4.2 million. That is better than year-end, but it comes after the establishment of a NIS 13.5 million bank line and in the shadow of the pending EDGE funding. It is relief, not self-funded flexibility.

The main financing move of 2025 was the Bank Mizrahi Tefahot credit agreement. In May, the subsidiary received a NIS 10 million line, and in November another NIS 3.5 million was added. The agreement allows funding of up to 50% of orders for 180 days at prime plus 3.35%, or invoice financing for 90 days at prime plus 2.6%. Against the line, the group deposited roughly NIS 1.2 million and granted security over assets, intellectual property, and receivables. In March 2026 the line was renewed for another year.

The right read is that the bank is helping the company bridge the gap between orders and production. That is positive. But it is doing so against collateral and in an order-backed funding structure, not through open-ended balance-sheet flexibility. Interest-rate sensitivity also remains relevant: a 1% move in prime reduces profit before tax by about NIS 122 thousand.

Leases are smaller in scale but still part of the story. The new site lifted lease liabilities to NIS 4.13 million and lease cash payments to NIS 550 thousand in 2025. This is not the central problem, but it is another sign that fixed commitments already increased to fit the next phase before the earnings power fully arrived.

Outlook

Before looking at 2026 directly, four non-obvious conclusions need to stay together:

• Backlog is already large enough to justify higher revenue expectations, but 2025 proved that backlog alone does not guarantee profitability.
• The bank line and EDGE improve the funding bridge, but neither replaces internal cash generation.
• Management is already speaking the language of serial production while 2025 margins still look like a penetration-and-development year.
• The real 2026 risk is not lack of demand, but the speed at which demand turns into recognized revenue, gross margin, and cash collection.

That is why 2026 looks like a proof year. Management frames the next year around unmanned-aircraft detection, maturing more products into serial offerings, deeper international expansion, and larger sales and marketing capacity. It also says that the advanced product developed for the tender it won has already been approved for serial production, with meaningful deliveries expected during 2026.

That sounds constructive, but the analytical translation needs to be sharper: 2026 counts as success only if three engines work together. First, backlog has to convert into revenue quickly. Second, gross margin has to improve after the setup phase. Third, cash burn has to ease materially. If only the first happens, the company could still exit 2026 with higher revenue but the same balance-sheet friction.

The main supporting datapoint is the NIS 44.18 million backlog at year-end 2025, more than 2x annual revenue. That sits on top of the ground-vehicle defense project, where total orders already reached NIS 24 million by the reporting date, and the March 11, 2026 follow-on order of roughly NIS 4 million with an expected half-year execution window. That gives much better visibility than the company had a year ago.

But there is a major caution built into the same evidence set. The company itself says that part of the order book is not yet revenue, and that realization timing depends on cancellation risk falling away and on actual delivery pace. That is exactly why 2026 is not an automatic breakout year. It is a proof year in which the numbers need to move from the order column into the revenue column, and then into the cash column.

The international-expansion story also needs discipline. The company is already active with NATO-country customers, works with a leading European integrator and with agents, and says it intends to deepen direct market penetration. EDGE may help materially on distribution and commercialization. But as long as the joint venture is optional and none of that future channel effect is visible in the numbers, the main impact is still financial and strategic rather than operating.

From a market-reading perspective over the short to medium term, investors are likely to focus on four checkpoints: full closing of the EDGE funding, delivery pace on the 2025 and 2026 orders, the first real sign that gross margin is recovering from the 2025 trough, and evidence that the customer base can widen without simply swapping one concentration for another.

Risks

Customer concentration is deeper than the word "strategic" suggests

The Ministry of Defense generated NIS 17.655 million in 2025, around 84% of revenue. The year-end receivable balance tied to that customer was also NIS 11.288 million. This is not only a large customer. It is dependence on one procurement system, one approval flow, and one payment cadence. Credit quality may be relatively comfortable. Revenue concentration and operating dependency are still very heavy.

Financing pressure changed form, but it did not disappear

The company did repay the investor loan and shareholder loans during 2025, but it did not move into a clean self-funded position. It replaced expensive investor funding with order-backed bank credit, while still depending on the completion of the EDGE investment. That is an improvement in capital structure, not the disappearance of financing pressure. In addition, year-end outstanding options still stood at 1.923 million for employees, advisors, and officers, with another 118,351 restricted share units outstanding. That sits on top of the potential dilution from EDGE.

Supplier concentration is being described more softly than it really behaves

The company states that it has no supplier dependency, but in the same section it says that one supplier accounts for about 30% of purchases, is defined as a national resource, and operates in a special relationship with the customer. The risk is therefore not supplier collapse. The risk is that the supplier-customer structure can affect ordering pace, component mix, and delivery timing.

Rates, FX, and manufacturing execution can still disrupt the read

Part of revenue is dollar-linked while a large part of the cost base, especially payroll, is in shekels. In 2025 the dollar weakened 12.5% against the shekel, and the company recorded NIS 151 thousand of FX expense. That was not the main story in 2025, but it remains a real cross-sector risk for a company trying to build export activity on top of a mostly local cost base. At the same time, the move into serial production increases execution risk. Any slippage in development cost, manufacturing approvals, or delivery pace can turn backlog into delayed economics rather than realized economics.

The external warning signal from the auditors also should not be ignored. They did not qualify the opinion, but they explicitly drew attention to the combination of losses, negative operating cash flow, and ongoing significant R&D expenditure. Management responds with a 15-month liquidity forecast. That is not a severe red flag, but it does mean the balance sheet is still part of the thesis rather than background noise.

Conclusions

Ein Shlishit exits 2025 with two parallel stories. The first is constructive: demand is real, backlog is real, the anchor customer is still there, production capacity has been built, and the funding bridge looks easier than before. The second is harder: none of that has yet translated into the economics of a business that can grow while also generating clean margin and cash.

The bottom line is that the company has already passed the question of whether it has technology and market relevance. It is still inside the tougher question of whether it can scale without repeatedly buying revenue through credit, inventory, and dilution. That is the line between an interesting technology story and a more mature business thesis.

Current thesis in one line: the orders and the technology are already there, but 2026 needs to prove that Ein Shlishit can convert serial production into margin and cash, not only into revenue.

What changed versus the earlier understanding: the story has shifted from demand proof to growth quality. By 2025 there is already backlog, manufacturing capacity, and the EDGE option, but it is also clear that the road there was paid for through margin sacrifice, inventory build, and short-term credit.

Strongest counter-thesis: 2025 may simply distort the economics downward. If the spending on the production line, the MEDUZA and ARGOS product work, and the inventory build were all front-loaded ahead of a larger delivery wave that already exists, then 2025 gross margin may represent a temporary trough rather than a normal earnings level.

What could change the market read over the short to medium term: full receipt of the EDGE proceeds, fast execution of the 2025 orders and the March 11, 2026 follow-on order, and visible gross-margin recovery in the next reports.

Why this matters: for a defense-technology company like this, it is not enough to prove that the technology works and orders exist. The company has to prove that the technology also creates business economics rather than only narrative momentum.

What must happen over the next 2 to 4 quarters for the thesis to strengthen, and what would weaken it: the thesis improves if gross margin recovers, operating cash burn eases, and revenue concentration falls. It weakens if inventory and credit continue rising faster than revenue, if the EDGE deal slips, or if order growth turns into reported sales without any parallel improvement in profit quality.